Screener / SEC EDGAR /CIK 0001607678 /10-K filed Feb 11, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Viking Therapeutics, Inc. VKTX

Compare with peers Embed
FY2025 at a glance

FY2025 in six numbers

XBRL, from each 10-K
RevenueStatements
$0 from $0 in FY2024
FY2016FY2025
Net incomeStatements
-$359.6M from -$110.0M in FY2024
FY2016FY2025
EPS (diluted)Statements
$-3.19 from $-1.01 in FY2024
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (26)
EPS (ttm)
-5.42
Sales (ttm)
0
Net income (ttm)
-627.2M
Sales growth
-
EPS growth
-
Sales Q/Q
-
Free cash flow
-
Gross margin
-
Oper. margin
-
Net margin
-
FCF margin
-
R&D / sales
-
Dividend
-
Debt/Eq
-
Curr. ratio
7.27
Cash
677.6M
Op. cash flow (ttm)
-462.6M
Quick ratio
7.27
Shares out.
127.5M
Shares Y/Y
+3.3%
Book / share
4.62
Cash / share
5.31
Sales / share
0.00
Asset turnover
0.00

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2016 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 0 Net income -359.6M
FY2016 revenue 0 · Revenues, 0001564590-18-004757 FY2016 net income -14.7M · NetIncomeLoss, 0001564590-18-004757 0 FY2016 FY2017 revenue 0 · RevenueFromContractWithCustomerExcludingAssessedTax, 0001564590-19-007584 FY2017 net income -20.6M · NetIncomeLoss, 0001564590-19-007584 0 FY2017 FY2018 revenue 0 · RevenueFromContractWithCustomerExcludingAssessedTax, 0001564590-20-006766 FY2018 net income -22.1M · NetIncomeLoss, 0001564590-20-006766 0 FY2018 FY2019 revenue 0 · RevenueFromContractWithCustomerExcludingAssessedTax, 0001564590-21-006406 FY2019 net income -25.8M · NetIncomeLoss, 0001564590-21-006406 0 FY2019 FY2020 revenue 0 · RevenueFromContractWithCustomerExcludingAssessedTax, 0001564590-22-004429 FY2020 net income -39.5M · NetIncomeLoss, 0001564590-22-004429 0 FY2020 FY2021 revenue 0 · RevenueFromContractWithCustomerExcludingAssessedTax, 0000950170-24-012322 FY2021 net income -55.0M · NetIncomeLoss, 0000950170-24-012322 0 FY2021 FY2022 revenue 0 · RevenueFromContractWithCustomerExcludingAssessedTax, 0000950170-25-027824 FY2022 net income -68.9M · NetIncomeLoss, 0000950170-25-027824 0 FY2022 FY2023 revenue 0 · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-26-046876 FY2023 net income -85.9M · NetIncomeLoss, 0001193125-26-046876 0 FY2023 FY2024 revenue 0 · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-26-046876 FY2024 net income -110.0M · NetIncomeLoss, 0001193125-26-046876 0 FY2024 FY2025 revenue 0 · RevenueFromContractWithCustomerExcludingAssessedTax, 0001193125-26-046876 FY2025 net income -359.6M · NetIncomeLoss, 0001193125-26-046876 0 FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing.

Growth per share, FY2015 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Book value per share +21.4% a year FY2021 $2.62 to FY2025 $5.67, 4 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 -$3.19$5.67-
Dec 31, 2024 -$1.01$8.07-
Dec 31, 2023 -$0.91$3.69-
Dec 31, 2022 -$0.90$1.89-
Dec 31, 2021 -$0.71$2.62-
Dec 31, 2020 ---
Dec 31, 2019 ---
Dec 31, 2018 ---
Dec 31, 2017 ---
Dec 31, 2016 ---
Dec 31, 2015 ---

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $715.6M
  • − All liabilities $76.7M
  • = Net current asset value $638.9M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $639.1M
  • = Tangible book value $639.1M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

VKTX against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Return on equity
-5.2%18.5%
-106.6%141st of 144 · median 9.2%
VKTX and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
VKTX Viking Therapeutics, Inc.$0 ----106.6%--
ROIV Roivant Sciences Ltd.$41.1M -71.6%--838.2%-8.6%-81.2%-
IDYA IDEAYA Biosciences, Inc.$36.5M ----38.5%-957.4%-
CRSP CRISPR Therapeutics AG$25.2M -90.6%---27.7%-0.36
CGON CG Oncology, Inc.$6.2M +255%---24.0%-0.00
SRRK Scholar Rock Holding Corp$570K -----1.16
All 162 companies in the group

Profitability

  • Return on equity below 15%
    -106.6%
  • A profit in 0 of 10 years

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

VKTX's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue0
FY2016: 0FY2017: 0FY2018: 0FY2019: 0FY2020: 0FY2021: 0FY2022: 0FY2023: 0FY2024: 0FY2025: 0 FY2017FY2019FY2021FY2023FY2025
Net income-359.6M
FY2016: -14.7MFY2017: -20.6MFY2018: -22.1MFY2019: -25.8MFY2020: -39.5MFY2021: -55.0MFY2022: -68.9MFY2023: -85.9MFY2024: -110.0MFY2025: -359.6M FY2017FY2019FY2021FY2023FY2025
EPS (diluted)-3.19
FY2016: -0.90FY2017: -0.79FY2018: -0.38FY2019: -0.36FY2020: -0.54FY2021: -0.71FY2022: -0.90FY2023: -0.91FY2024: -1.01FY2025: -3.19 FY2017FY2019FY2021FY2023FY2025
Diluted shares112.7M
FY2016: -FY2017: -FY2018: -FY2019: -FY2020: -FY2021: 77.2MFY2022: 76.8MFY2023: 94.3MFY2024: 109.0MFY2025: 112.7M FY2017FY2019FY2021FY2023FY2025

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-11.1M-14.8M-18.8M-24.8M-21.8M-47.6M-48.4M-73.4M-87.8M-278.7M
Stock-based pay (added back)1.8M1.5M2.6M3.7M5.8M6.1M8.7M16.8M29.7M40.8M
Buybacks229-----6.8M---
Investing cash flow3.0M-1.7M-265.7M7.5M41.6M38.0M54.8M-179.1M-553.4M341.4M
Financing cash flow10.3M22.4M300.3M887K950K6.9M4.2M271.4M612.5M76.4M

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)1.8M1.5M2.6M3.7M5.8M6.1M8.7M16.8M29.7M40.8M
Operating lease cost----319K320K----
Right-of-use assets---598K321K25K1.4M1.1M1.0M85K
Operating lease liabilities---662K359K29K1.6M1.3M1.1M137K
Finance lease liabilities--0-------

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/VKTX/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.